Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.

[1]  S. Sleijfer,et al.  Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples , 2020, British Journal of Cancer.

[2]  David R. Jones,et al.  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.

[3]  Michael P. Morrissey,et al.  Use of Circulating Tumor DNA for Cancer Immunotherapy , 2019, Clinical Cancer Research.

[4]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[5]  S. Ju,et al.  Examination of Plasma Cell-Free DNA of Glioma Patients by Whole Exome Sequencing. , 2019, World neurosurgery.

[6]  Yao-Zhen Song,et al.  Treatment of urinary incontinence after total hysterectomy with acupuncture , 2019, Medicine.

[7]  Jing Wang,et al.  Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions , 2019, Front. Oncol..

[8]  F. Nielsen,et al.  Application of cell-free DNA for genomic tumor profiling: a feasibility study , 2019, Oncotarget.

[9]  Keval Patel,et al.  Enhanced detection of circulating tumor DNA by fragment size analysis , 2018, Science Translational Medicine.

[10]  O. Delattre,et al.  Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis , 2018, International journal of cancer.

[11]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[12]  F. Nielsen,et al.  Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors , 2018, Oncotarget.

[13]  N. Girard,et al.  Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy , 2018, Nature Reviews Clinical Oncology.

[14]  Laurie Kurihara,et al.  ERASE-Seq: Leveraging replicate measurements to enhance ultralow frequency variant detection in NGS data , 2018, PloS one.

[15]  T. Pons,et al.  Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies , 2018, Clinical Cancer Research.

[16]  D. García-Olmo,et al.  Liquid biopsy by NGS: differential presence of exons (DPE) in cell‐free DNA reveals different patterns in metastatic and nonmetastatic colorectal cancer , 2018, Cancer medicine.

[17]  Brooke L. Billman,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  O. Delattre,et al.  Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma , 2017, Clinical Cancer Research.

[19]  Etienne Rouleau,et al.  Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients , 2017, PloS one.

[20]  Nikhil Wagle,et al.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.

[21]  A. Chinnaiyan,et al.  Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. , 2017, Cancer discovery.

[22]  Kui Wu,et al.  Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. , 2017, Journal of hepatology.

[23]  M. Nykter,et al.  Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer , 2017, Clinical Cancer Research.

[24]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[25]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[26]  Stefan Sleijfer,et al.  Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions , 2017, Molecular oncology.

[27]  V. Velculescu,et al.  The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA , 2016, Clinical Cancer Research.

[28]  E. Dahl,et al.  Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients , 2016, PloS one.

[29]  N. Dhomen,et al.  Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Marie-Cécile Le Deley,et al.  Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial , 2016, Clinical Cancer Research.

[31]  Carlos Caldas,et al.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer , 2015, Nature Communications.

[32]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[33]  Nicholas J. Wang,et al.  Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease , 2015, PloS one.

[34]  B. Teh,et al.  MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations , 2015, Scientific Reports.

[35]  N. Tunariu,et al.  Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration , 2015, Clinical Cancer Research.

[36]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[37]  Nicolai J. Birkbak,et al.  Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Johan Lindberg,et al.  Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma , 2014, PloS one.

[40]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[41]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[42]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[43]  M. Wiese,et al.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[45]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[46]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..